Abstract
This study validates the EuroPOND Event-Based Model (EBM) for Alzheimer’s disease (AD) staging using both standardized research data (ADNI) and heterogeneous real-world clinical data (REMEMBER). The model successfully identifies a consistent biological progression from cerebrospinal fluid (CSF) changes to cognitive decline and structural brain atrophy. Notably, the model distinguishes between amnestic and non-amnestic mild cognitive impairment (MCI), offering a tool for precision recruitment in clinical trials.
Introduction: Beyond Coarse Clinical Labels
Clinical diagnosis of Alzheimer’s disease typically relies on broad categories: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and Alzheimer’s Disease Dementia (ADD). However, these labels often fail to capture the underlying biological progression. Two patients sharing an MCI diagnosis may exist at vastly different stages of the disease's biological "clock." Furthermore, models developed on "pristine" research datasets like ADNI often struggle with the "messy" reality of clinical practice, where data is frequently missing or non-standardized. This research addresses the need for a robust, biomarker-driven staging system applicable across diverse clinical environments.
Methods: Event-Based Modeling (EBM)
The researchers employed an enhanced version of the EuroPOND EBM toolbox. EBM is a probabilistic, data-driven approach that determines the most likely sequence of biomarker changes—referred to as "events"—without requiring pre-defined clinical cut-offs.
The model tracked nine key variables:
- CSF Biomarkers: Amyloid-beta (Aβ1-42), P-tau181, and T-tau.
- Clinical Scores: MMSE (global cognition) and RAVLT (memory).
- MRI-derived Volumes: Hippocampus, temporal, parietal, and frontal cortices (computed via icobrain dm).
The model produces a 10-stage scale (0–9), where Stage 0 indicates no abnormalities and Stage 9 signifies that all biomarkers have reached an abnormal state.
Key Insights: The Biological Cascade
The model confirmed a consistent "cascade" of events: CSF changes occur first, followed by cognitive decline, and finally structural brain atrophy.
MCI Heterogeneity
A critical finding was the differentiation between amnestic MCI (aMCI) and non-amnestic MCI (naMCI). The EBM revealed that aMCI patients are significantly further along the AD trajectory, with 54% residing in the most advanced stages compared to only 38% of naMCI patients. This suggests that naMCI may frequently be driven by non-AD pathologies, highlighting the model's utility for precision patient screening.
Results and Validation
The model, trained on the ADNI dataset (n=1737), was successfully validated on two independent cohorts:
- Research Cohort (University of Antwerp): 119 patients with complete multimodal data.
- Real-world Cohort (REMEMBER): 686 patients from nine Belgian dementia clinics. Despite missing CSF data in the REMEMBER cohort, the model effectively staged patients, demonstrating high generalizability.
Outlier analysis further proved the model's biological accuracy. For instance, "healthy" controls placed in high stages often possessed positive Amyloid-PET scans (preclinical AD), while MCI patients in Stage 0 often had symptoms attributable to non-AD causes, such as depression.
Conclusion and Future Directions
The EuroPOND EBM provides an objective, biomarker-driven framework for AD staging that remains robust even with real-world clinical data. While the current model assumes a single sequence of progression, future work will utilize Sustain (Subtype and Stage Inference) models to account for AD's inherent heterogeneity and different disease "flavors." Incorporating longitudinal data will further enhance the model's predictive power for multi-center clinical trials.
Summary updated